2024
Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, Myers A, Nogueras‐Gonzalez G, Navai N, Dinney C, Guo C, Kamat A. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 2024, 133: 733-741. PMID: 38374533, DOI: 10.1111/bju.16293.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerImmediate radical cystectomyCancer-specific survivalMetastasis-free survivalProgression-free survivalT1 substagingOverall survivalRadical cystectomyPathology reportsBladder cancerHigh-grade non-muscle-invasive bladder cancerPatients treated with bacillus Calmette-GuerinAssociated with poor progression-free survivalInstitutional review board-approved retrospective studyPatients treated with BCGPoor progression-free survivalLamina propriaAssociated with upstagingBCG-treated patientsCalculate overall survivalTreated with BCGKaplan-Meier methodHigh-grade patientsMultivariate Cox modelInvasive characteristics
2023
Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Contieri R, Grajales V, Tan W, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras‐Gonzalez G, Guo C, Navai N, Dinney C, Kamat A. Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU International 2023, 133: 63-70. PMID: 37442564, PMCID: PMC10787034, DOI: 10.1111/bju.16127.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinCancer-specific mortalityCompeting-risk regression analysisCohort of patientsOncological outcomesFood and Drug AdministrationHG recurrenceAssociated with adverse oncologic outcomesHigh-gradeImpact of ageInstitutional review board-approved retrospective studyBacillus Calmette-Guerin instillationsIntravesical BCGCumulative incidence of progressionAdverse oncologic outcomesIncidence of progressionAssociation of advanced ageUnited States Food and Drug AdministrationStates Food and Drug AdministrationCumulative incidence methodPredictors of progressionStudy's primary outcomeBCG instillationRegression analysisClinical trial design for non-muscle-invasive bladder cancer
Tan W, Hall E, Kamat A, Kelly J. Clinical trial design for non-muscle-invasive bladder cancer. Nature Reviews Urology 2023, 20: 575-576. PMID: 37328547, DOI: 10.1038/s41585-023-00789-0.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCystectomyHumansNeoplasm InvasivenessNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsBacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal?
Tan W, Grajales V, Bree K, Li R, Nogueras‐Gonzalez G, Navai N, Dinney C, Kamat A. Bacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal? BJU International 2023, 132: 384-386. PMID: 37246493, DOI: 10.1111/bju.16087.Peer-Reviewed Original Research
2018
Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories
Mossanen M, Wang Y, Szymaniak J, Tan W, Huynh M, Preston M, Trinh Q, Sonpavde G, Kibel A, Chang S. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal Of Urology 2018, 37: 2059-2065. PMID: 30446799, DOI: 10.1007/s00345-018-2550-x.Peer-Reviewed Original ResearchMeSH KeywordsAgedHealth Care CostsHumansMaleNeoplasm InvasivenessRisk AssessmentUrinary Bladder NeoplasmsConceptsBladder cancerProgression to muscle-invasive diseaseNon-muscle-invasive bladder cancerHigh-risk disease patientsEORTC risk calculatorHigh-risk NMIBCManagement of NMIBCMuscle-invasive diseaseLow-risk tumorsBiologically heterogeneous diseaseHigh-risk diseaseSurveillance of patientsMethodsA Markov modelLong-term surveillanceHigh-risk groupPatient risk groupsOverall cost of careCost of surveillanceCost of careIntermediate-riskSurveillance cystoscopyExpensive malignanciesIndex patientPatient basisNMIBCIntravesical device-assisted therapies for non-muscle-invasive bladder cancer
Tan W, Kelly J. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nature Reviews Urology 2018, 15: 667-685. PMID: 30254383, DOI: 10.1038/s41585-018-0092-z.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerElectromotive drug administrationDevice-assisted therapiesBladder cancerHyperthermic chemotherapyDevice-assisted treatmentsIntravesical adjuvant treatmentHigh-risk diseaseResults of randomized trialsRisk of recurrenceRisk of progressionAlternative to BCGEffective treatment optionSingle-arm study designBladder cancer diagnosisBCG failureRandomized controlled trialsMaintenance regimensAdjuvant treatmentPatient cohortTreatment optionsRandomized trialsDrug AdministrationControlled trialsClinical guidelines
2015
Silence of MACC1 expression by RNA interference inhibits proliferation, invasion and metastasis, and promotes apoptosis in U251 human malignant glioma cells
SUN L, LI G, DAI B, TAN W, ZHAO H, LI X, WANG A. Silence of MACC1 expression by RNA interference inhibits proliferation, invasion and metastasis, and promotes apoptosis in U251 human malignant glioma cells. Molecular Medicine Reports 2015, 12: 3423-3431. PMID: 26043756, PMCID: PMC4526050, DOI: 10.3892/mmr.2015.3886.Peer-Reviewed Original ResearchConceptsShort hairpin RNAFluorescence-activated cell sortingInhibition of cell proliferationRNA interferenceCell invasionCell apoptosisCell proliferationPhase cell cycle arrestG0/G1 phase cell cycle arrestCell cycle arrestEnhancement of apoptosisExpression levelsInhibition of cell invasionGlioma cellsHuman malignant glioma cellsHuman glioma progressionExpression levels of MACC1MACC1 silencingColony formGlioma progressionCycle arrestCaspase-3Genetic therapeutic strategiesExpression silencingGlioma cell proliferation
2014
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer
Gurung P, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan W, Feber A, Crabb S, Short S, Freeman A, Powles T, Hoskin P, West C, Kelly J. Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer. International Journal Of Cancer 2014, 136: 709-720. PMID: 24917520, DOI: 10.1002/ijc.29022.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerMuscle-invasive bladder cancer patientsTissue-microarrayBladder cancerAssociated with survivalPredictive of survivalMethylation-specific PCRColony forming assayLoss of expressionRadical cystectomyRadiotherapy trialsRadiosensitising effectPrognostic valueMechanism of gene silencingRadiotherapyResponse to ionising radiationClinical biomarkersPatientsProtein expressionCancerMeta-analysisDNA damage responseCystectomySurvivalBladder